Need Help?

MMPU Group Molecular Pediatric Oncology (MPO)

Contact Information

MMPU Group Molecular Pediatric Oncology Data Access Committee
mpo-dac@mmpu.de

Request Access

This DAC controls 3 datasets

Dataset ID	Description	Technology	Samples
EGAD00001004459	Each dataset cosist of WES data from 5 samples (1 patient): original leukemia initial diagnosis T-ALL, original leukemia relapse T-ALL, PDX derived of initial diagnosis T-ALL, PDX derived of relapse T-ALL, remission (normal control)	Illumina HiSeq 2000 Illumina HiSeq 2500 NextSeq 500	164
EGAD50000000831	In this study, we conducted single cell full length total RNA sequencing (VASA-seq) on 13 matched pediatric T-ALL PDX samples at initial diagnosis and relapse, along with 5 non-relapsing PDX samples collected at initial diagnosis. We identified a subpopulation of T-ALL cells with stem-like cell features that expands substantially at relapse indicating resistance to first-line therapy. Chemotherapy resistance was further validated through functional testing: Two samples were subjected to in-vitro drug testing, treated with Cytarabine for three days, followed by single-cell transcriptomic analysis using 10x Genomics. Additionally, in-vivo drug testing was conducted on one sample, involving re-engraftment into mice and treatment with a combination of Vincristine, Doxorubicin, and Dexamethasone. Single-cell transcriptomic analysis using 10x Genomics was performed after 0, 15 and 30 days of treatment.	Illumina NovaSeq 6000 NextSeq 550	77
EGAD50000001168	Targeted deep sequencing data of 386 T-ALL patients in several high-risk T-ALL genes. Samples were prepared according to Agilent's HaloPlex HS Target Enrichment Protocol and sequenced as 75bp paired-end reads. Data is available as paired-end FASTQ files for each sample.	NextSeq 2000	386